Skip to main content
ZNTL
NASDAQ Life Sciences

Zentalis' Azenosertib Advances: FDA Aligns on Phase 3, DENALI Readout Expected for Accelerated Approval

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.67
Mkt Cap
$192.91M
52W Low
$1.01
52W High
$3.95
52W Position info
164% above low
Off High info
32% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.01 on light trading volume (0.3× avg).

Summary

Zentalis Pharmaceuticals announced its full-year 2025 financial results and significant operational advancements for its lead oncology asset, azenosertib. The company completed enrollment for DENALI Part 2a, a registration-intended study, and achieved alignment with the FDA on the design for its Phase 3 ASPENOVA confirmatory trial for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Critically, Zentalis anticipates topline data from the DENALI Part 2 trial by year-end 2026, which could potentially support accelerated approval. Financially, the company reported a strong cash position of $245.9 million as of December 31, 2025, extending its cash runway into late 2027, well beyond the anticipated DENALI readout. This comprehensive update provides significant de-risking for the lead program and offers substantial financial stability, making 2026 a pivotal year for the company. Investors should closely watch for the DENALI Part 2 readout and the initiation of the ASPENOVA trial in the first half of 2026.

At the time of this announcement, ZNTL was trading at $2.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.9M. The 52-week trading range was $1.01 to $3.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Nov 09, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.43 info
Change: -$0.3092 (-18%) info
Market Cap: $133.642M info
ZNTL
Oct 23, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.43 info
Change: -$0.8792 (-38%) info
Market Cap: $133.642M info
ZNTL
Oct 19, 2026, 2:31 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $1.43 info
Change: -$0.8542 (-37%) info
Market Cap: $133.642M info
ZNTL
Oct 18, 2026, 6:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.43 info
Change: -$0.6792 (-32%) info
Market Cap: $133.642M info
ZNTL
Aug 19, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $3.82
Real-time Price: $1.43 info
Change: -$2.39 (-63%) info
Market Cap: $133.642M info